Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/AUTS2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/AUTS2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/AUTS2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/AUTS2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AUTS2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/AUTS2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/AUTS2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AUTS2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/AUTS2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/AUTS2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AUTS2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00074099 | Prostate | BPH | axonogenesis | 98/3107 | 418/18723 | 1.68e-04 | 1.45e-03 | 98 |
GO:00604919 | Prostate | BPH | regulation of cell projection assembly | 51/3107 | 188/18723 | 1.73e-04 | 1.48e-03 | 51 |
GO:00105918 | Prostate | BPH | regulation of lamellipodium assembly | 17/3107 | 42/18723 | 2.01e-04 | 1.64e-03 | 17 |
GO:00064796 | Prostate | BPH | protein methylation | 49/3107 | 181/18723 | 2.42e-04 | 1.93e-03 | 49 |
GO:00082136 | Prostate | BPH | protein alkylation | 49/3107 | 181/18723 | 2.42e-04 | 1.93e-03 | 49 |
GO:012003210 | Prostate | BPH | regulation of plasma membrane bounded cell projection assembly | 50/3107 | 186/18723 | 2.53e-04 | 2.00e-03 | 50 |
GO:00165716 | Prostate | BPH | histone methylation | 40/3107 | 141/18723 | 3.09e-04 | 2.37e-03 | 40 |
GO:00300327 | Prostate | BPH | lamellipodium assembly | 24/3107 | 72/18723 | 3.85e-04 | 2.83e-03 | 24 |
GO:00310566 | Prostate | BPH | regulation of histone modification | 42/3107 | 152/18723 | 4.09e-04 | 2.97e-03 | 42 |
GO:19019832 | Prostate | BPH | regulation of protein acetylation | 25/3107 | 77/18723 | 4.62e-04 | 3.32e-03 | 25 |
GO:01200345 | Prostate | BPH | positive regulation of plasma membrane bounded cell projection assembly | 31/3107 | 105/18723 | 6.72e-04 | 4.50e-03 | 31 |
GO:00166017 | Prostate | BPH | Rac protein signal transduction | 16/3107 | 42/18723 | 6.86e-04 | 4.58e-03 | 16 |
GO:00605608 | Prostate | BPH | developmental growth involved in morphogenesis | 58/3107 | 234/18723 | 8.28e-04 | 5.40e-03 | 58 |
GO:20007562 | Prostate | BPH | regulation of peptidyl-lysine acetylation | 21/3107 | 63/18723 | 8.71e-04 | 5.62e-03 | 21 |
GO:00515682 | Prostate | BPH | histone H3-K4 methylation | 20/3107 | 59/18723 | 9.02e-04 | 5.78e-03 | 20 |
GO:00486758 | Prostate | BPH | axon extension | 33/3107 | 120/18723 | 1.76e-03 | 1.01e-02 | 33 |
GO:00435433 | Prostate | BPH | protein acylation | 58/3107 | 243/18723 | 2.14e-03 | 1.19e-02 | 58 |
GO:00180225 | Prostate | BPH | peptidyl-lysine methylation | 35/3107 | 131/18723 | 2.23e-03 | 1.23e-02 | 35 |
GO:00165733 | Prostate | BPH | histone acetylation | 39/3107 | 152/18723 | 2.86e-03 | 1.50e-02 | 39 |
GO:19901387 | Prostate | BPH | neuron projection extension | 43/3107 | 172/18723 | 3.06e-03 | 1.60e-02 | 43 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AUTS2 | SNV | Missense_Mutation | novel | c.3679C>A | p.Leu1227Met | p.L1227M | Q8WXX7 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
AUTS2 | SNV | Missense_Mutation | | c.1429N>G | p.Leu477Val | p.L477V | Q8WXX7 | protein_coding | deleterious(0) | benign(0.359) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
AUTS2 | SNV | Missense_Mutation | | c.2284N>C | p.Gly762Arg | p.G762R | Q8WXX7 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
AUTS2 | SNV | Missense_Mutation | | c.2285N>T | p.Gly762Val | p.G762V | Q8WXX7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
AUTS2 | SNV | Missense_Mutation | | c.2335N>T | p.Asp779Tyr | p.D779Y | Q8WXX7 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-BH-A0DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
AUTS2 | SNV | Missense_Mutation | novel | c.3664C>G | p.Pro1222Ala | p.P1222A | Q8WXX7 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
AUTS2 | insertion | Nonsense_Mutation | novel | c.2058_2059insTAGGCAGTTGTATCCAGCACTGCGGGCGGAAATGATTCCAT | p.Leu687Ter | p.L687* | Q8WXX7 | protein_coding | | | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AUTS2 | SNV | Missense_Mutation | | c.1549N>T | p.Pro517Ser | p.P517S | Q8WXX7 | protein_coding | tolerated(0.21) | probably_damaging(0.93) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
AUTS2 | SNV | Missense_Mutation | | c.2674G>C | p.Glu892Gln | p.E892Q | Q8WXX7 | protein_coding | deleterious(0.01) | possibly_damaging(0.542) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
AUTS2 | SNV | Missense_Mutation | | c.1150G>A | p.Ala384Thr | p.A384T | Q8WXX7 | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |